Amorphous Solid Dispersion and Its Role in Drug Stability

An amorphous solid dispersion (ASD) embeds a drug in a polymer matrix so that the drug molecules sit in a disordered, non-crystalline arrangement rather than in the rigid lattice they naturally prefer. That disordered state makes the drug dissolve faster and more completely, but it also makes the drug want to snap back into crystal form over time. The entire purpose of the polymer carrier is to resist that recrystallization and keep the drug stable long enough to be manufactured, shipped, stored, and swallowed. How well any particular ASD accomplishes this depends on a web of interacting factors, from the strength of molecular bonds between drug and polymer to how much moisture the formulation absorbs on a humid day.

Why Crystalline Drugs Need an Alternative

A large and growing share of drug candidates coming out of pharmaceutical pipelines dissolve poorly in water. Their molecules pack tightly into crystal lattices held together by strong, repeating intermolecular forces. Breaking apart that lattice is the energetic barrier a drug must overcome to dissolve in the gut. When a drug is converted to its amorphous form, that lattice disappears. The molecules are arranged randomly, more like a liquid frozen in place, and the energy needed to get them into solution drops substantially. Polymeric carriers have become the standard way to lock a drug into this advantageous amorphous state, forming what the field calls an amorphous solid dispersion.¹

The catch is thermodynamic instability. An amorphous drug is in a higher-energy state than its crystalline counterpart, and left to its own devices, it will eventually recrystallize, losing the solubility advantage that justified making an ASD in the first place. The polymer’s job is to slow or prevent that recrystallization for the product’s entire shelf life. This is where the science of drug stability in ASDs gets interesting, and where formulation choices have enormous consequences.

How Polymers Hold the Amorphous State Together

The most important stabilizing mechanism is hydrogen bonding between drug and polymer molecules. When a drug sits in a crystal, its molecules hydrogen-bond to each other in a repeating pattern. In an ASD, the polymer interrupts those self-associations and forms new hydrogen bonds with the drug instead. Research on nifedipine dispersions showed that the polymer PVP formed the strongest hydrogen bonds with the drug, and this translated directly into the greatest resistance to recrystallization. Adding just 20% PVP by weight increased the structural relaxation time of the dispersion roughly 65-fold, while the same amount of a weaker-bonding polymer (HPMCAS) produced only about a 5-fold increase. A third polymer, poly(acrylic acid), showed no detectable drug-polymer interaction and offered no stability benefit at all.²

Solid-state NMR studies of indomethacin dispersions confirmed this picture from a different angle. In pure amorphous indomethacin, the drug’s carboxylic acid groups form dimers with each other, a stepping stone toward crystallization. Adding PVP or a PVP-vinyl acetate copolymer disrupted those self-associations: at a 50/50 drug-polymer weight ratio, the carboxylic acid dimers were almost completely broken up.³

Hydrogen bonding alone is not always enough, though. Work on the anti-inflammatory drug nabumetone found that even when a polymer could form hydrogen bonds with the drug, it only prevented crystallization if the polymer also dissolved well in the amorphous drug phase. If the polymer was essentially immiscible, those hydrogen bonds could not form at the molecular level needed to matter.⁴

Glass Transition Temperature and Why Storage Conditions Matter

Every amorphous material has a glass transition temperature, the temperature below which it behaves like a brittle glass and above which it softens and flows. For ASD stability, the glass transition temperature sets an approximate boundary. Below it, molecular motion slows dramatically, and the drug molecules lack the freedom to rearrange themselves into crystals. Above it, molecules move more freely and crystallization accelerates.

A common rule of thumb has been to store ASDs at least 50 degrees Celsius below their glass transition temperature. Early research supported this by showing that amorphous pharmaceutical solids can still experience meaningful molecular mobility at temperatures up to 50 degrees below their glass transition.⁵ This means the glass transition is not a hard cutoff. Molecular rearrangement does not stop at the transition; it just slows down.

More recent work has refined the picture. Researchers found that for predicting when a drug actually starts to recrystallize during storage, the glass transition temperature of a secondary, faster molecular motion (called the beta-relaxation) is a better predictor than the primary glass transition. When amorphous nifedipine was stored below this secondary transition temperature, it remained amorphous, but stored above it, recrystallization began.⁶ For the cholesterol-lowering drug ezetimibe, structural relaxation at room temperature was predicted to take only about 22 days, matching the experimentally observed recrystallization time. Without a stabilizing polymer, that drug simply cannot survive in the amorphous form at room temperature.⁷

One way polymers help is by raising the glass transition temperature of the mixture. If a drug has a low glass transition on its own, blending it with a high-glass-transition polymer pushes the mixture’s transition upward, effectively making the material more glassy and less mobile at room temperature. In some cases the drug can even act as the component that raises the polymer’s glass transition. Curcumin, for example, has a glass transition well above that of a poly(ester amide) carrier, and dispersions of curcumin in this polymer showed intermediate glass transition values, with the drug acting as an anti-plasticizer that stiffened the matrix.⁸ A similar anti-plasticizing effect was observed when amorphous indomethacin was dispersed in a PVA copolymer, where specific hydrophilic and hydrophobic interactions between the drug and polymer raised the glass transition and also prevented crystallization through the polymer’s low tendency to absorb water.⁹

Drug-Polymer Miscibility and the Risk of Phase Separation

For a drug and polymer to form a truly molecular-level mixture, they have to be miscible. If they are not, the ASD can separate into drug-rich and polymer-rich regions, and in the drug-rich zones, crystallization happens quickly because there is little polymer around to stop it.

Predicting miscibility before committing to expensive manufacturing is a major goal of formulation science. Researchers use thermodynamic phase diagrams that map out, for a given drug-polymer pair, how much drug the polymer can hold at different temperatures. These diagrams distinguish between the amount of crystalline drug that can dissolve into the polymer (the solubility limit) and the broader region where the amorphous drug and polymer will remain mixed without separating into phases (the miscibility limit). At drug loadings below the solubility limit, the dispersion is thermodynamically stable. Between the solubility and miscibility limits, the system is metastable and may eventually phase-separate but will resist doing so for a meaningful period. Above the miscibility limit, phase separation is thermodynamically spontaneous.¹⁰

These phase diagrams are constructed using interaction parameters that quantify how favorably a drug and polymer mix. When the interaction is favorable (the drug “likes” the polymer), the miscibility window is wide and higher drug loadings can be achieved. When it is unfavorable, even modest drug loads risk phase separation.¹¹ This is why polymer selection is not just about finding a polymer that forms hydrogen bonds with the drug. The drug must also be soluble or at least miscible in the polymer matrix at the loading and storage temperature needed for the product.

Manufacturing Methods and Their Stability Trade-Offs

The two dominant manufacturing routes for ASDs are hot-melt extrusion (HME) and spray drying (SD). Each produces an amorphous product, but the resulting material can behave quite differently during storage.

In hot-melt extrusion, the drug and polymer are melted together and pushed through a die, producing a dense extrudate. In spray drying, the drug and polymer are dissolved in a solvent, atomized into fine droplets, and rapidly dried. The rapid solvent removal in spray drying tends to produce highly porous particles with large surface areas, which dissolve quickly but may also absorb more moisture.

A comparative study of felodipine ASDs found that spray-dried formulations released the drug faster than melt-extruded ones for both polymer types tested, but in some cases the extruded formulations showed better physical stability, with crystallization detected in the spray-dried version at certain drug-polymer ratios.¹² A more recent study echoed this, finding that hot-melt extruded samples showed superior stability against recrystallization, while spray-dried samples achieved higher dissolution rates.¹³

The picture is not always so clean-cut, however. A study using accelerated stability testing on nifedipine ASDs found the opposite pattern for physical stability: spray-dried powders showed a single glass transition (indicating a well-mixed system), while the extruded material showed two glass transitions, a sign that the drug and polymer had already begun to phase-separate. On the other hand, the extruded formulations had better chemical stability, while the spray-dried versions were more sensitive to moisture-driven chemical degradation.¹⁴ The lesson is that no single manufacturing method wins on every stability metric. The best choice depends on the specific drug, polymer, and what kind of instability is the bigger concern for that combination.

Moisture as a Destabilizer

Water is the most common environmental threat to ASD stability. Absorbed moisture acts as a plasticizer, lowering the glass transition temperature and increasing molecular mobility, which opens the door to recrystallization. Some polymers are much more hygroscopic than others, and this makes polymer selection a practical packaging and storage decision as well as a thermodynamic one.

Research on celecoxib ASDs showed that at high humidity (94% relative humidity), dispersions containing PVP underwent amorphous-amorphous phase separation before eventually crystallizing, while other polymer systems crystallized directly without that intermediate step.¹⁵ PVP is particularly water-hungry, which is one reason many newer ASD products favor less hygroscopic polymers like HPMCAS, despite PVP’s strong hydrogen-bonding ability. It is a classic trade-off: PVP may form the best molecular interactions, but those interactions weaken once water molecules compete for the same bonding sites.

A review of FDA-approved ASD drug products found that all recommend storage at controlled room temperature, with none requiring refrigeration.¹⁶ This reflects confidence that modern ASD formulations, when properly designed and packaged, can maintain stability under real-world conditions without special cold-chain handling.

When Physical Stability Comes at a Chemical Cost

Most ASD development focuses on physical stability, meaning preventing recrystallization. But the very interactions that keep a drug amorphous can sometimes accelerate chemical degradation. A study of two different drug-HPMCAS systems found that ionic bonding between a pyridine group on the drug and a succinyl group on the polymer stabilized one formulation against crystallization. However, in another formulation of similar composition, an additional hydrogen bond brought a reactive hydroxyl group into close proximity with the succinyl group, triggering a chemical reaction that produced an unwanted ester byproduct. The interaction that was good for physical stability was bad for chemical stability.¹⁷

This is a critical point for formulators: you cannot optimize exclusively for physical stability without checking the chemical consequences. A polymer that forms wonderfully strong interactions with a drug may also catalyze degradation reactions that limit shelf life in a different way.

The Spring and Parachute in Dissolution

An ASD’s stability story does not end when it sits on a pharmacy shelf. When a patient swallows the tablet, the drug has to dissolve and stay dissolved long enough to be absorbed. The amorphous form dissolves quickly and can produce drug concentrations in the gut that temporarily exceed the crystalline drug’s solubility limit, a state called supersaturation. This rapid concentration spike is known informally as the “spring.” But supersaturated solutions are unstable, and the drug can precipitate back out. The polymer in the ASD acts as a “parachute,” slowing that precipitation and holding the drug in solution during the absorption window.¹⁸

Different polymers vary widely in their ability to sustain supersaturation. Studies on the model compound alpha-mangostin ranked polymer effectiveness in inhibiting both crystal nucleation and crystal growth in solution, with PVP outperforming HPMC and Eudragit. Viscosity measurements ruled out a simple thickening effect: the polymers were not just slowing diffusion. Instead, specific drug-polymer interactions in solution were responsible for keeping the drug from crystallizing out.¹⁹ Complementary research confirmed that increasing polymer effectiveness against nucleation and growth directly increased the degree of supersaturation achieved.²⁰

This means the same polymer has two jobs: keep the drug amorphous during storage (solid-state stability) and keep the drug from crashing out of solution in the gut (solution-state stability). A polymer that excels at one is not guaranteed to excel at the other, which is why polymer screening involves both solid-state aging tests and dissolution experiments.

Predicting Shelf Life Without Waiting Years

Pharmaceutical companies cannot afford to wait two or three years to learn whether an ASD formulation is stable. Predictive models have become an essential part of early-stage development. One approach uses mechanistic modeling that incorporates supersaturation, molecular diffusivity, and the energy cost of forming crystal surfaces. By coupling nucleation and crystal growth equations, researchers can simulate the recrystallization timeline for a given drug-polymer system and compare predictions against accelerated stability data. Published results showed good agreement between model predictions and experimental observations.²¹

A more practical approach combines crystallization kinetics theory with a few fast measurements above the glass transition temperature, plus one measurement below it, to determine the parameters needed for shelf-life prediction at any drug loading, temperature, and humidity. This method was verified for ASDs stored at room temperature under both dry (10% relative humidity) and moderate humidity (60% relative humidity) conditions, and it allows predictions to be generated within days rather than months.²² Analytical tools such as second harmonic generation imaging can detect trace amounts of crystallinity in final dosage forms, providing a sensitive check on whether predictions match reality.²³

What Happens After the ASD Is Made

Even a perfectly stable ASD intermediate can be destabilized during downstream processing. Milling, a common step for turning extruded material into particles suitable for tableting, introduces mechanical energy that can increase molecular mobility and create drug-rich amorphous domains that are prone to crystallization. Research on several drug-polymer combinations showed that formulations loaded below the drug’s solubility in the polymer (true molecular dispersions) survived milling without issue. But supersaturated dispersions, where more drug was present than the polymer could truly dissolve, were destabilized by the same milling conditions.²⁴

This finding has a clear practical implication for formulators: knowing the drug’s solubility in the polymer is not just an academic exercise. It determines how aggressively you can process the material without undoing the stability you worked to achieve. A formulation that looks stable on a shelf may fail after milling if the drug loading sits above the solubility boundary.

Ternary Systems and Surfactant Additions

When a two-component drug-polymer ASD does not perform well enough, formulators sometimes add a third ingredient, often a surfactant, to create a ternary dispersion. Surfactants can improve processing by lowering melt viscosity during hot-melt extrusion, allowing polymers like HPMCAS (which has a high melt viscosity) to be extruded at lower temperatures. Work comparing several surfactants found that TPGS (a vitamin E-derived surfactant) produced the most similar solid-state properties between spray-dried and extruded ternary ASDs, though it had minimal effect on the underlying drug-polymer interactions.²⁵

Adding surfactants introduces its own stability considerations. Some surfactants are themselves prone to phase separation or can alter the glass transition behavior of the mixture. The celecoxib work described earlier showed that ternary systems containing PVP were susceptible to amorphous-amorphous phase separation under high humidity, a step that preceded crystallization.¹⁵ Ternary formulations can also be combined with lipid-based delivery systems. When a ritonavir-containing ASD was incorporated into a supersaturable self-nanoemulsifying system, the physical stability of the formulation improved from about 48 hours to one month under ambient conditions, and the in vivo exposure in rats increased roughly threefold compared to a conventional lipid formulation containing three times more lipid.²⁶

Why the Solubility Advantage Can Reverse

One of the more counterintuitive findings in ASD research is that forming a solid dispersion does not always increase solubility. The drug’s solubility from an ASD depends on the state and composition of whatever undissolved material remains after the ASD contacts water. Water can absorb into the undissolved ASD, changing the drug’s thermodynamic state within the matrix. Depending on the specifics of the drug-polymer-water interaction, this can actually lower the drug’s driving force to dissolve compared to the pure amorphous form. In other words, the same stabilization that prevents crystallization can also reduce the thermodynamic push toward dissolution.²⁷

This means formulators cannot simply assume that making an ASD will always improve drug delivery. The polymer-drug-water system needs to be understood as a whole. A formulation that is wonderfully stable on the shelf could underperform during dissolution if the stabilizing interactions are too strong for the drug to escape the matrix efficiently.